Products & Services · Cost of Sales
Adcirca — Cost of Sales
United Therapeutics Adcirca — Cost of Sales decreased by 70.6% to $1.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 61.5%, from $2.60M to $1.00M. Over 4 years (FY 2021 to FY 2025), Adcirca — Cost of Sales shows a downward trend with a -14.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2017
Last reportedQ1 2026
Rolls up toTotal Cost of Revenue
How to read this metric
An increase relative to revenue may signal rising manufacturing costs or supply chain inefficiencies, while a decrease suggests improved production margins.
Detailed definition
Includes the direct costs attributable to the production and distribution of a specific pharmaceutical product. This typ...
Peer comparison
Commonly reported as Cost of Goods Sold (COGS) for specific product segments in biotech filings.
Metric ID:
uthr_segment_adcirca_cost_of_salesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.30M | $6.10M | $3.50M | $4.00M | $4.70M | $4.40M | $4.70M | $3.10M | $3.10M | $3.40M | $2.70M | $2.60M | $2.60M | $3.10M | $1.80M | $2.60M | $2.70M | $4.40M | $3.40M | $1.00M |
| QoQ Change | — | -40.8% | -42.6% | +14.3% | +17.5% | -6.4% | +6.8% | -34.0% | +0.0% | +9.7% | -20.6% | -3.7% | +0.0% | +19.2% | -41.9% | +44.4% | +3.8% | +63.0% | -22.7% | -70.6% |
| YoY Change | — | — | — | — | -54.4% | -27.9% | +34.3% | -22.5% | -34.0% | -22.7% | -42.6% | -16.1% | -16.1% | -8.8% | -33.3% | +0.0% | +3.8% | +41.9% | +88.9% | -61.5% |
Range$1.00M – $10.30M
CAGR-38.8%
Avg YoY Growth-10.7%
Median YoY Growth-19.3%
Current Streak2 quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's adcirca — cost of sales?
- United Therapeutics (UTHR) reported adcirca — cost of sales of $1.00M in Q1 2026.
- How has United Therapeutics's adcirca — cost of sales changed year-over-year?
- United Therapeutics's adcirca — cost of sales decreased by 61.5% year-over-year, from $2.60M to $1.00M.
- What is the long-term trend for United Therapeutics's adcirca — cost of sales?
- Over 4 years (2021 to 2025), United Therapeutics's adcirca — cost of sales has grown at a -14.0% compound annual growth rate (CAGR), from $23.90M to $13.10M.
- What does adcirca — cost of sales mean?
- The direct costs incurred to manufacture and deliver a specific product to market.